Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
Shamash
Jonathan
J
Powles
Tom
T
Wilson
Peter
P
Ansell
Wendy
W
Oliver
Timothy
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D016207:Cytokines / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000077146:Irinotecan; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016685:Mitomycin / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D011379:Prognosis
D016207:Cytokines; D016685:Mitomycin; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin